The ABM team offers another innovative technology in the field of oncology. GENEXUS system can identify biomarkers associated with major oncology diseases:
- Bladder cancer;
- Breast Cancer;
- Colorectal cancer;
- endometrial cancer;
- Esophageal cancer;
- Stomach cancer;
- Gastroesophageal adenocarcinoma. Gastrointestinal stromal tumor of the gastrointestinal tract;
- Tumors of the head and neck;
- Melanoma;
- Non-small cell lung cancer
- Pancreatic cancer;
- Soft tissue sarcoma.
Genexus determines the effectiveness of a specific therapy (immune, chemical, targeted), which helps to start timely and relevant treatment. This is the first, fully automated NGS system that requires minimal intervention by specialist and guarantees accuracy.
Figure 1: The Genexus System is two instruments connected by one software.
• is a flexible, cost-effective system. Requires only 18.5 - 29.5 hours for the analysis response;
• Research requires a small amount of material, 10 nanograms;
• It is also possible to do the analysis from blood plasma.
The Genexus system also helps determine whether the patient has a genetic predisposition to various tumors.